Pages that link to "Q34385127"
Jump to navigation
Jump to search
The following pages link to Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. (Q34385127):
Displaying 50 items.
- A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo (Q21136366) (← links)
- Initial impact of the sequencing of the human genome (Q22122172) (← links)
- PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Q24187425) (← links)
- Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation (Q24294486) (← links)
- Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly (Q24298534) (← links)
- The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications (Q24299848) (← links)
- Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c (Q24300790) (← links)
- Molecular and functional analysis of two new MTTP gene mutations in an atypical case of abetalipoproteinemia (Q24301635) (← links)
- Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation (Q24303660) (← links)
- The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR (Q24303965) (← links)
- Self-association of human PCSK9 correlates with its LDLR-degrading activity (Q24306591) (← links)
- Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase (Q24307641) (← links)
- Mutations in NOTCH1 cause aortic valve disease (Q24307999) (← links)
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice (Q24311328) (← links)
- A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol (Q24336810) (← links)
- Common variants at 30 loci contribute to polygenic dyslipidemia (Q24598765) (← links)
- Targeted capture and massively parallel sequencing of 12 human exomes (Q24615381) (← links)
- The PCSK9 decade (Q24615397) (← links)
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (Q24646644) (← links)
- Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine (Q24652495) (← links)
- LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor (Q24656186) (← links)
- Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy (Q25255216) (← links)
- Unmet Needs in LDL-C Lowering: When Statins Won't Do! (Q26741705) (← links)
- PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab (Q26747776) (← links)
- New developments in atherosclerosis: clinical potential of PCSK9 inhibition (Q26783407) (← links)
- Insights into blood lipids from rare variant discovery (Q26799138) (← links)
- Cardiovascular pharmacogenomics: current status and future directions (Q26801183) (← links)
- Exploring predisposition and treatment response--the promise of genomics (Q26851609) (← links)
- Genome-scale neurogenetics: methodology and meaning (Q26859474) (← links)
- New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs (Q26863369) (← links)
- Genetics of lipid traits and relationship to coronary artery disease (Q26995252) (← links)
- Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk (Q27003094) (← links)
- Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases (Q27009477) (← links)
- Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia (Q27013494) (← links)
- Molecular biology of PCSK9: its role in LDL metabolism (Q27488922) (← links)
- Molecular basis for LDL receptor recognition by PCSK9 (Q27649779) (← links)
- Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells (Q27653836) (← links)
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates (Q27655476) (← links)
- A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S] (Q27665195) (← links)
- Genome editing: the road of CRISPR/Cas9 from bench to clinic (Q28066970) (← links)
- New Era of Lipid-Lowering Drugs (Q28072298) (← links)
- Zebrafish small molecule screens: Taking the phenotypic plunge (Q28073655) (← links)
- PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future (Q28083595) (← links)
- Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform (Q28085421) (← links)
- Therapeutic genome editing: prospects and challenges (Q28087380) (← links)
- Insights from exome sequencing for endocrine disorders (Q28088772) (← links)
- Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase (Q28115283) (← links)
- Development and applications of CRISPR-Cas9 for genome engineering (Q28241526) (← links)
- Multiplex amplification of large sets of human exons (Q28253118) (← links)
- The proprotein convertases and their implication in sterol and/or lipid metabolism (Q28258161) (← links)